Business Context and Reporting Period
This filing is a Form 10-Q for Brooks Automation, Inc. (the predecessor name associated with Azenta, Inc.), covering the three months ended December 31, 2013, the first quarter of fiscal 2014. Brooks provides automation, vacuum, instrumentation, global services, and life science systems. Semiconductor capital equipment represented approximately 55% of revenue during the quarter.
Financial Highlights
| Metric | Q1 FY2014 | Q1 FY2013 | Change |
|---|---|---|---|
| Total revenue | $124.6 million | $98.0 million | 27% increase |
| Gross profit | $44.7 million | $29.2 million | 53% increase |
| Gross margin | 35.8% | 29.7% | +6.1 percentage points |
| Operating income (loss) | $3.9 million | $(13.1) million | Improved by $17.0 million |
| Net income (loss) attributable to Brooks | $3.4 million | $(9.2) million | Returned to profitability |
| Diluted EPS | $0.05 | $(0.14) | Improved by $0.19 |
| Cash flow from operations | $8.5 million | $5.1 million | Increase of $3.4 million |
Operating margin was approximately 3.2%, compared with negative 13.3% in the prior-year quarter. The improvement reflected higher volume, favorable product mix, increased fixed-cost absorption, and lower warranty and material costs. R&D was $13.2 million, SG&A was $26.8 million, and restructuring and other charges were $0.7 million versus $4.7 million in the prior-year period.
At December 31, 2013, cash and cash equivalents were $78.0 million, and total marketable securities were $97.7 million, producing aggregate cash, cash equivalents, and marketable securities of $175.7 million. Current assets were $321.0 million versus current liabilities of $85.5 million. The filing does not report outstanding borrowings or debt principal; interest expense was immaterial. The company had approximately $5.8 million of letters of credit outstanding.
Material Changes Versus the Prior Comparable Period
- Product revenue increased 30% to $100.3 million, while services revenue increased 17% to $24.3 million.
- Brooks Product Solutions revenue increased 41% to $88.7 million, primarily from stronger semiconductor equipment demand and a full quarter of Crossing Automation revenue.
- Brooks Global Services revenue increased 12% to $23.7 million.
- Brooks Life Science Systems revenue decreased 14% to $12.2 million, despite $1.3 million of revenue from the Matrical acquisition, due to lower automated sample management system and software sales.
- Revenue benefited from the October 2012 Crossing acquisition and the August 2013 acquisition of certain Matrical life science assets.
- Cash flow from investing activities changed from $0.1 million provided in the prior-year quarter to $8.3 million used, primarily due to net purchases of marketable securities and capital expenditures; the prior-year period included the $56.0 million cash outflow for the Crossing acquisition.
- The company paid a quarterly dividend of $5.4 million, or $0.08 per share, and declared another $0.08-per-share dividend payable March 28, 2014.
Outlook, Risks, Contingencies, and Unusual Items
- Management stated that it believed available resources were adequate to fund planned working capital and capital expenditures for the next twelve months. No specific revenue or earnings guidance was provided.
- Results remain exposed to the cyclical semiconductor capital equipment market and broader global economic conditions. Management noted that longer-term liquidity needs are difficult to predict and additional financing may not be available on favorable terms.
- Restructuring activities included life science administrative consolidation and the transition of certain Polycold manufacturing to a third-party manufacturer. Total Polycold severance and retention charges are expected to be approximately $1.3 million, with the remaining costs to be recorded through fiscal 2014.
- The company recorded an additional $0.4 million impairment charge related to the Celigo product line; the full $2.0 million impairment had been identified as of September 30, 2013.
- Income taxes were a $1.7 million provision, compared with a $3.7 million benefit in the prior-year quarter. Management maintained valuation allowances against certain U.S. and foreign deferred tax assets.
- One customer represented 13% of quarterly revenue, compared with no customer exceeding 10% in the prior-year quarter.
- The company was subject to ordinary-course legal proceedings but believed none would have a material adverse effect; management cautioned that outcomes remain inherently unpredictable.
- Foreign-currency exposure remained material: 29% of sales were in currencies other than the U.S. dollar, and management estimated that a hypothetical 10% currency movement would change net income by approximately $0.9 million.
Important Facts for Investors to Verify
- Confirm the company identity and period mapping: the filing is for Brooks Automation, Inc., not an entity named Azenta, Inc., and covers the quarter ended December 31, 2013.
- Assess whether the improved profitability was sustained after the semiconductor-driven revenue rebound and whether the Life Science Systems segment recovered from its revenue decline.
- Review the impact, timing, and cash cost of the Polycold outsourcing and other restructuring programs.
- Evaluate the recoverability of goodwill, acquired intangible assets, deferred tax assets, and the Celigo-related assets.
- Monitor customer concentration, semiconductor cycle exposure, foreign-exchange sensitivity, dividend sustainability, and the absence of reported debt despite other contractual and contingent obligations.